Introduction
Signaling events initiated by cytokines within the bone marrow microenvironment are necessary for the viability and development of normal B-cells. Such events are equally important for the maintenance of many B cell malignancies as well, including Waldenstrom's macroglobulinemia (WM), a lymphoplasmacytic lymphoma characterized by high levels of serum IgM. 1, 2 One of the most prominent signaling cascades activated by cytokines is the Janus kinase family (JAK)/signal transducers and activators of transcription (STAT) pathway composed of four JAK proteins (JAKs1-3, Tyk2) and seven STAT proteins (STATs 1-6, including STAT5A and STAT5B). 3 Hyperactivation of these proteins, either in response to heightened cytokine signaling or secondary to activating mutations within the JAK/STAT pathway, leads to carcinogenesis, with numerous reports suggesting an association between constitutive STAT5 activation and uncontrolled cellular proliferation in hematologic malignancies. [4] [5] [6] [7] [8] Despite a high degree of amino acid sequence homology, STAT5A and STAT5B are distinct transcription factors, with evidence indicating both overlapping and nonredundant functional activities for these isoforms in solid tumors. 9 
Methods

Cell Lines and Reagents
The WM cell lines, MWCL-1, BCWM.1 and RPCI-WM1 were cultured as described. 2 CD19 + CD138 + WM cells were isolated from the bone marrows of consenting patients using positive selection beads. The STAT5 inhibitors, N′-((4-Oxo-4H-chromen-3yl)methylene) nicotinohydrazide and N1-(11H-indolo[3,2-c]quinolin-6-yl)-N2,N2dimethylethane-1,2-diamine (IQDMA) were purchased from Calbiochem.
Immunohistochemistry
Paraffin-embedded bone marrow specimens were stained with anti-human pSTAT5 and visualized as outlined previously. 2 shRNA-mediated knockdown of STAT5A and STAT5B STAT5A-and STAT5B-targeting shRNAs in the doxycycline-inducible pTRIPZ vector system were purchased from Open Biosystems. Recombinant lentiviral particles were expressed following transient transfection of HEK293T cells using the TransLenti Viral Packaging System (Open Biosystems). Viral supernatant was then used to transduce MWCL-1 cells and, after 48 hours, cells were selected with puromycin.
Specificity and efficiency of doxycycline-induced knockdown was determined after 72 hours by western blotting.
Enzyme-linked immunoabsorbent assay (ELISA)
Cell-free supernatants were collected, and the concentration of IgM was determined according to the manufacturer's protocol (Human IgM ELISA Kit; Bethyl Laboratories, Inc).
Proliferation Assay
Cells were cultured with either a STAT5 inhibitor or doxycycline for 48 or 72 hours, respectively. Tritiated thymidine ( 3 H-TdR; 5.0 Ci/mmol [185 GBq/mmol] (Amersham) was added 18 hours prior to scintillation counting.
Immunoprecipitation and Immunoblotting
Cell lysates from BCWM.1 and MWCL-1 cells were incubated overnight with either anti-STAT5A or anti-STAT5B antibodies followed by the addition of Protein G Dynabeads (Invitrogen) for an additional 24 hours. Beads were collected using a magnet and heated for ten minutes in LDS Sample Loading Buffer. Protein was separated by SDS-PAGE. Following transfer onto nitrocellulose membranes, blots were probed using antibodies targeted towards either pSTAT5 (Y694/Y699) (Abcam), STAT5A or STAT5B 
Results and Discussion
Constitutive activation of STAT5 in WM
Constitutive STAT signaling is associated with the pathogenesis and progression of many malignancies. 4, 6, 14 ( Figure 1B ). Sequential staining of bone marrow specimens revealed STAT5 phosphorylation in both CD20 + -and CD138 + -expressing cell populations ( Figure 1C ). Furthermore, immunoprecipitation experiments revealed baseline phosphorylation of both the STAT5A and STAT5B isoforms in the BCWM.1 and MWCL-1 cell lines ( Figure   1D ). Together these data indicate that STAT5 is constitutively phosphorylated in malignant WM B cells.
Biological effects of STAT5 knockdown in WM
Hyperactivation of STAT5 has been reported in other hematological malignancies including Hodgkin lymphoma, acute myeloid leukemia and acute lymphocytic leukemia, For personal use only. on October 24, 2017. by guest www.bloodjournal.org From and inhibition of STAT5 phosphorylation either chemically or using siRNA-mediated approaches has been observed to significantly enhance apoptosis and limit cellular proliferation. 4, 15 We have employed both methodologies here to assess the biological relevance of constitutive STAT5 phosphorylation in WM. Decreasing the expression of either STAT5A or STAT5B using isoform-specific, doxycycline-inducible shRNA significantly decreased IgM levels as compared to MWCL-1 cells transduced with an empty vector shRNA (Figure 2A, 2B) . These results were subsequently confirmed in BCWM.1 cells (data not shown). Interestingly, the STAT5A-and STAT5B-mediated decreases in IgM secretion do not appear to occur secondary to decreases in overall cell number, as inhibition of neither STAT5A nor STAT5B had an effect on the level of cellular proliferation ( Figure 2C ). STAT5 has been previously reported to drive cellular proliferation through activation of cyclin D1. 16 However, it is possible that both isoforms need to be inhibited to see effects on proliferation, as knocking down only STAT5A or STAT5B may lead to compensation by the other isoform, an effect that has been observed following inhibition of other STAT proteins. 17, 18 These experiments were then repeated using known small molecule inhibitors of both isoforms of STAT5, N'-((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide and IQDMA. 19, 20 A dose-dependent decrease in IgM secretion was observed following incubation of WM cell lines with both small molecule inhibitors, providing the first data to indicate that STAT5 regulates IgM secretion by malignant B cells (Figures 2E, 2G) . The small molecule inhibitors also significantly decreased cellular proliferation, albeit at slightly higher concentrations than those needed to affect IgM levels. (Figures 2F, 2H) .
These results support the existence of a compensatory mechanism between STAT5A For personal use only. on October 24, 2017. by guest www.bloodjournal.org From 1 0 and STAT5B such that both isoforms need to be inhibited before cellular proliferation is affected.,
In conclusion, we have identified high levels of STAT5 activation in malignant WM B cells. As inhibition of both STAT5 isoforms either alone or together led to significant reductions in IgM levels, addition of a STAT5 inhibitor to current treatment protocols could provide a useful clinical strategy for lowering IgM levels in patients with WM. 
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